In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms

International Journal of Antimicrobial Agents

Volumn 34, Issue 4, 2009, Pages 326-332

  Miceli, Marisa H ^a,b   Bernardo, Stella M ^a,b   Lee, Samuel A ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

Amphotericin; Antifungal agents; Biofilms; Candida albicans; Caspofungin; Doxycycline; Fluconazole

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; DOXYCYCLINE; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; FUNGAL METABOLISM; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 67651214054     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.04.011     Document Type: Article

References (29)

1. Ramage G., Saville S.P., Thomas D.P., and Lopez-Ribot J.L. Candida biofilms: an update. Eukaryot Cell 4 (2005) 633-638
2. Mermel L.A., Farr B.M., Sherertz R.J., Raad I.I., O'Grady N., Harris J.S., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32 (2001) 1249-1272
3. Bestul M.B., and Vandenbussche H.L. Antibiotic lock technique: review of the literature. Pharmacotherapy 25 (2005) 211-227
4. Raad I., Chatzinikolaou I., Chaiban G., Hanna H., Hachem R., Dvorak T., et al. In vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob Agents Chemother 47 (2003) 3580-3585
5. Raad I., Darouiche R., Dupuis J., Abi-Said D., Gabrielli A., Hachem R., et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 127 (1997) 267-274
6. Raad I., Hanna H., Dvorak T., Chaiban G., and Hachem R. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother 51 (2007) 78-83
7. Johnson D.C., Johnson F.L., and Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 13 (1994) 930-931
8. Schinabeck M.K., Long L.A., Hossain M.A., Chandra J., Mukherjee P.K., Mohamed S., et al. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother 48 (2004) 1727-1732
9. Choi H.W., Shin J.H., Jung S.I., Park K.H., Cho D., Kee S.J., et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 51 (2007) 1520-1523
10. Jacobson M.J., Piper K.E., Nguyen G., Steckelberg J.M., and Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 52 (2008) 2242-2243
11. Katragkou A., Chatzimoschou A., Simitsopoulou M., Dalakiouridou M., Diza-Mataftsi E., Tsantali C., et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 52 (2008) 357-360
12. Kuhn D.M., George T., Chandra J., Mukherjee P.K., and Ghannoum M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46 (2002) 1773-1780
13. Shuford J.A., Rouse M.S., Piper K.E., Steckelberg J.M., and Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 194 (2006) 710-713
14. Beggs W.H., Sarosi G.A., and Walker M.I. Synergistic action of amphotericin B and rifampin against Candida species. J Infect Dis 133 (1976) 206-209
15. Medoff G., Kobayashi G.S., Kwan C.N., Schlessinger D., and Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B. Proc Natl Acad Sci USA 69 (1972) 196-199
16. Schaumann R.F., and Shah P.M. Effect of amphotericin B alone or in combination with rifampicin on phagocytosis of Candida species by human polymorphonuclear leukocytes. Methods Find Exp Clin Pharmacol 14 (1992) 753-758
17. Edwards Jr. J.E., Morrison J., Henderson D.K., and Montgomerie J.Z. Combined effect of amphotericin B and rifampin on Candida species. Antimicrob Agents Chemother 17 (1980) 484-487
18. Lew M.A., Beckett K.M., and Levin M.J. Antifungal activity of four tetracycline analogues against Candida albicans in vitro: potentiation by amphotericin B. J Infect Dis 136 (1977) 263-270
19. Lew M.A., Beckett K.M., and Levin M.J. Combined activity of minocycline and amphotericin B in vitro against medically important yeasts. Antimicrob Agents Chemother 14 (1978) 465-469
20. Oliver B.G., Silver P.M., Marie C., Hoot S.J., Leyde S.E., and White T.C. Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology 154 (2008) 960-970
21. El-Azizi M. Enhancement of the in vitro activity of amphotericin B against the biofilms of non-albicans Candida spp. by rifampicin and doxycycline. J Med Microbiol 56 (2007) 645-649
22. Gillum A.M., Tsay E.Y., and Kirsch D.R. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198 (1984) 179-182
23. Ramage G., and Lopez-Ribot J.L. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med 118 (2005) 71-79
24. Nobile C.J., and Mitchell A.P. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 8 (2006) 1382-1391
25. Ramage G., VandeWalle K., Bachmann S.P., Wickes B.L., and Lopez-Ribot J.L. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 46 (2002) 3634-3636
26. Viale P., Pagani L., Petrosillo N., Signorini L., Colombini P., Macri G., et al. Antibiotic lock-technique for the treatment of catheter-related bloodstream infections. J Chemother 15 (2003) 152-156
27. Chamilos G., Lewis R.E., Albert N., and Kontoyiannis D.P. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 51 (2007) 2257-2259
28. Melo A.S., Colombo A.L., and Arthington-Skaggs B.A. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 51 (2007) 3081-3088
29. Wiederhold N.P. Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Curr Opin Infect Dis 20 (2007) 574-578